

#### JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

CIN: L74899DL1978PLC009181

JPL/Stock-Corr-2013	November 11th, 2016				
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051	The Manager Listing Agreement The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.				
CM Quote : JAGSNPHARM	Scrip Code : 507789				
	NG OF BOARD OF DIRECTORS OF TCALS LIMITED HELD ON 11.11.2016				

Sir.

- Performance of the 2nd Quarter and Half Year ended 30.09.2016 (Un-audited) was placed before the Board having reviewed by the Audit Committee. The issue was discussed.
- Approval of 2nd Quarter and Half Year performance ended 30.09.2016 was approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Limited Review statement is enclosed.
- Other routine matters were discussed by Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks,
- The meetings commence at 12.00 noon and concluded at 2.15 p.m.

New Delhi

Thanking you,

Yours faithfully,

For JAGSONPAL PHARMACE ON CAUS DIMITED

R K KAPOOR

COMPLIANCE OFFICER & COMPANY SECRETARY

Factory: 20 K.M. Mathura Road, Post Office Amar Nagar. Faridabad-121003 (India) Phone: 0091-95129-2275952, 2275953
Factory: Plot No 14, 15, 16, 55 56, 57, Sector-5, IIE. Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand
CIN No. L74899DLI978PLC009181



#### JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

# CIN No:- L74899DL1978PLC009181 JAGSONPAL PHARMACEUTICALS LIMITED Extract of Unaudited Financial Results for the Quarter ended 30th September, 2016

Rs. in lacs

S_No	o. Particulars	Quarter Ended 30-09-2016 Un-audited	Quarter Ended 30-06-2016 Un-audited	Quarter Ended 30-09-2015 Un-audited	6 Monthly Ended 30-09-2016 Un-audited	6 Monthly Ended 30-09-2015 Un-audited	12 Months Ended 31-03-2016 Audited
1	Total Income from operations (net)	4001.90	4011.02	3296.96	8012.92	6995.71	14348.79
2	Net Profit / (Loss) before Tax	62.93	80.17	59.85	143.10	123.00	407.52
3	Net Profit / (Loss) after Tax	50.33	64.14	43.95	114.47	90.40	325.42
4	Equity Share Capital (face Value Rs. 5/-)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
5	Reserves (excluding revaluation Reserves as shown in the Balance of Previous Year						7742.63
6	Earning per Shares (Rs.) (Face value : Rs. 5/- each) not annualized Basic & Diluted E P S						
	Before Extraordinary Item	0.19	0.24	0.17	0.44	0.35	1.24
	After Extraordinary Items	0.19	0.24	0.17	0.44	0.35	1.24

The above is an extarct of the detailed format of Quarterly Financial Results filed with the stock Exchanges under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations , 2015. The full format of the Quarterly Financial results are available on the website of the Bombay Stock exchange Ltd. At http://bseindia.com and National Stock Exchanges of India Ltd. At http://www.nseindia.com and also on the Company's website at http://www.jagsonpal.com.

maceur

There are no exceptional & extraordinary items during the above periods.

for JAGSONPAL PHARMACEUTICALS LIMITED

RAJPAL SINGH KOCHHAR Managing Director DIN: 00059492

Place : New Delhi Date : 11/11/2016



#### JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA) Fax: 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

Unaudited Financial Results for the Quarter / Half year ended 30.09.2016

Rs. in lacs

	Particulars	3 months ended 30.09.2016 Unaudited	3 months ended 30.06.2016 Unaudited	3 months ended 30.09.2015 Unaudited	6 Months ended 30.09.2016 Unaudited	6 Months ended 30.09.2015 Unaudited	12 Months Ended 31.03.2016 Audited
1	Income from operations						
а	Net sales/Income from Operations (Net of excise duty)	4001.90	4011.02	3296.96	8012.92	6995.71	14348.79
b	Other Operating Income	14.02	13.15	30.94	27.17	30.94	59.26
	Total Income from operations (net)	4015.92	4024.17	3327.90	8040.09	7026.65	14408.05
2	Expenses						
a	Cost of materials consumed	1212.16	1673.9	2164.71	2886.06	3474.73	5627.89
b	Purchases of stock-in-trade	192.14	374.99	267.62	567.13	385.02	906.68
C.	Changes in inventories of finished goods,	283.42	-422.43	-1147.36	-139.01	-640.27	-622.24
d.	Employee benefits expenses	1011.44	1116.11	967.46	2127.55	1791.06	3783.71
e.	Depreciation and amortisation expense	72.80	70.43	73.08	143.23	142.22	309.36
f.	Other expenses	1094.02	1036.16	825.27	2130.18	1513.19	3471.80
100	Total expenses	3865.98	3849.16	3150.78	7715.14	6665.95	13477.20
3	Profit from Operations before Other Income,						
	Finance Cost and Exceptional items (1-2)	149.94	175.01	177.12	324.95	360.70	930.85
4	그러 보는 이 회장에 가지 이번 없는 내가면 먹는 맛이 있다면 나는 것이 되었다면 이번 사람이 되었다면 하는 사람들이 있다면 하다 하다면 하다.	0.06	0.03	3.41	0.09	6.31	6.38
5	Profit from ordinary activities before finance	150.00	175.04	180.53	325.04	367.01	937.23
	cost and Exceptional items (3+4)	innons.	5.79.797.11				
6	Finance Cost	87.07	94.87	120.68	181.94	244.01	529.71
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	62.93	80.17	59.85	143.10	123.00	407.52
8	Exceptional Items						
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	62.93	80.17	59.85	143,10	123.00	407.52
10	Tax expense	12.60	16.03	15.90	28.63	32.60	82.10
11	Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	50.33	64.14	43.95	114.47	90.40	325.42
12	Extraordinary Items (net of tax expense Rs.lacs)	)					
13	Net Profit(+)/Loss(-) for the period(11-12)	50.33	64.14	43.95	114.47	90.40	325.42
14	Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
15	그 나이 나이들이 얼마를 가지하다면 하는 가입니다. 이 기가 있는 이 사람들이 되었다면 하는데 되었다면 하는데 되었다면 하는데						7742.63
16	Earnings Per Share (before extraordinary items)						
a.	Basic (Rs.)	0.19	0.24	0.17	0.44	0.35	1.24
b.	Diluted (Rs.)	0.19		0.17	0.44	0.35	1.24
Note		2500	2000		374	= 200	100

 The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 11, 2016.

2) The Company operates in one reportable business segment i.e. 'Pharmaceuticals'.

Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period

The above results are available on website of the company www.jagsonpal.com.

By Order of the Board

For Jagsonpal Pharmaceuticals Limited

Place: New Delhi Date: 11.11.2016 S Limited

Rajpal Singh Kochhar Managing Director DIN No 00059492

## Statement of Assets and Liabilities

Rs. In lacs

Rs. Rs. In lacs

Α	EQUITY AND LIABILITIES	As at	As at	В	ASSETS	As at		As at
	10	30.09.2016	31.03.2016		7	30.09.2016	3 11.41	1.03.2016
		Unaudited	Audited			Unaudited	A	Audited
1	Shareholders' funds			1	Non-current assets			
	(a) Share Capital	1309.90	1309.90		(a) Fixed Assets	5104.85	5	5158.41
	(b) Reserves and surplus	8641.02	8526.55		(b) Goodwill	3.00		3.00
*	Sub-total - Shareholders' funds	9950.92	9836.45		(c) Non-current investments	0.05		0.05
					(d) Deferred tax assets (net)	0.00		0.00
2	Share application money pending allotment	0.00	0.00		(e) Long term loans and advance	682.89		670.88
					(f) Other non-current assets	0.00		0.00
3	Minority interest	0.00	0.00		Sub-total - Non-current assets	5790.79	5	5832.34
4	Non-current liabilites							
	(a) Long term borrowings	0.00	0.00					
	(b) Deferred tax liabilities (net)	360.56	360.86					
	(c) Other long term liabilities	0.00	0.00					
	(d) Long term provisions	0.00	0.00					
	Sub-total - Non-current liabilities	360.56	360.86	2	Current assets			
					(a) Current investments			
5	Current liabilities				(b) Inventories	4115.76	3	3983.75
	(a) Short term borrowing	1473.29	3849.26		(c) Trade receivables	4540.80	4	4169.02
	(b) Trade payables	957.31	972.68		(d) Cash and Cash equivalents	1340.12	1	1553.33
	(c) Other current liabilities	3645.77	661.30		(e) Short term loans and advance	876.64		389.74
	(d) Short term provisions	276.26	247.63		(f) Other current assets	0.00		0.00
	Sub-Total - Current liabilities	6352.63	5730.87		Sub-Total - Current assets	10873.32	10	10095.84
	TOTAL - EQUITY AND LIABILITIES	16664 11 ma	Ce//15928.18		TOTAL - ASSETS	16664.11	15	15928.18

Cs.

## P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre, Babar Road, New Delhi - 110 001

Ph. (O): 23413486

E-mail: sureshsethi62@yahoo.com

The Board of Director Jagsonpal Pharmaceuticals Limited T-210 J, Shahpur Jat New Delhi - 110049

### SUBJECT: LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") the Quarter ended 30.09.2016 which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the Quarter ended 30th September, 2016" (the "statement"). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI, 2015 (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations 2015) which has been initialed by us for identification purposes.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review of Interim Financial Information Performed by Independednt Auditor of the entity" by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) rule 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO., Chartered Accountants

Place : New Delhi Date : 11.11.2016 NEW DECHI

SURESH SETHI PARTNER F.R. No. 000632N Membership No. 89318